Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC. 31622732 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE High tumor mutational burden (TMB) and PD-L1 expression are leading biomarkers in metastatic non-small cell lung cancer (NSCLC) and predict favorable response to checkpoint inhibitors. 31550464 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels. 31610828 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE <b>Introduction</b>: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).However, specific patient groups (e.g. patients with activating <i>epidermal growth factor receptor</i> [<i>EGFR]</i> mutations) do not appear to derive benefit from immune checkpoint inhibitor (ICI) monotherapy. 31829747 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE This concept was applied to the use of noninvasive plasma epidermal growth factor receptor (EGFR) mutation testing in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to guide treatment with EGFR tyrosine kinase inhibitors (TKIs). 31125533 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE To determine factors associated with survival in de novo stage IV, non-small cell lung cancer (NSCLC) patients possessing epidermal growth factor receptor mutations (EGFRmut<sup>+</sup> ) receiving tyrosine kinase inhibitors (TKI) in the first-line setting. 31486229 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE We performed a retrospective review of 18 patients with histologically proven (+) EGFR (+) mutation metastatic NSCLC (mNSCLC) treated with 75 mg/d erlotinib as starting dose. 31567201 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE We collected data from EGFR TKI-naive patients with metastatic NSCLC, harboring EGFR exon 18 mutations and EGFR combined mutations treated with first- or second-generation EGFR TKIs. 30563752 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE We conducted an intervention study involving 126 individuals with confirmed activating epidermal growth factor receptor mutation-positive stage IV NSCLC who received icotinib hydrochloride as first-line therapy between January 2014 and January 2016; their caregivers were also included in the study. 29731164 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE The clinical data of patients with brain metastatic NSCLC who had EGFR-sensitive mutation and followed between January 2014 and January 2016 was retrospectively analyzed. 31128009 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Despite their remarkable efficacy in metastatic non-small cell lung cancer (NSCLC), EGFR- and ALK-targeted therapies have not been shown to confer any survival benefit in stage III disease, even in subsets of patients with driver mutations. 30711973 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE The aim of this study was to investigate the prevalence, characteristics, and clinical outcomes of metastatic NSCLC harboring uncommon EGFR mutation at Thailand's largest national tertiary hospital. 31315599 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE A 66-year-old man was diagnosed with relapsed stage IV non-small cell lung cancer with an EGFR mutation in exon 21 (L858R) 2 years after stereotactic body radiotherapy. 31486987 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE A high pretreatment PLR is independently associated with poor survival in stage IV NSCLC with MPE and in a subgroup of epidermal growth factor receptor and anaplastic lymphoma kinase wild-type NSCLC. 30886226 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE The RELAY regimen is a viable new treatment option for the initial treatment of EGFR-mutated metastatic NSCLC. 31591063 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Male, ever-smoker and positive PD-L1 are indicative of benefit to ICIs in metastatic non-small-cell lung cancer. 30730276 2019
Entrez Id: 238
Gene Symbol: ALK
ALK
0.100 Biomarker disease BEFREE A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer. 31583605 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. 30515719 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE The second-generation EGFR-TKI dacomitinib has also recently been approved for the first-line treatment of EGFRm positive metastatic NSCLC. 31568888 2019
Entrez Id: 238
Gene Symbol: ALK
ALK
0.100 GeneticVariation disease BEFREE Only for the small proportion of patients with metastatic NSCLC and genomic-driven tumors with EGFR or anaplastic lymphoma kinase (ALK)-sensitizing mutations (5%-15%), and possibly <i>BRAF</i> mutations and <i>ROS</i> rearrangements, have initial treatment recommendations remained unchanged, with specific tyrosine kinase inhibitors as the preferred therapy. 30642913 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater. 30955977 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE To assess the utility of the <b>cobas</b> EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with <i>EGFR</i>-mutated (<i>EGFR</i>m; Ex19del and/or L858R) advanced or metastatic non-small cell lung cancer (NSCLC) from the FLAURA study (NCT02296125). 31439584 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE <b>Case presentation:</b> A 66-year-old gentleman with metastatic non-small-cell lung cancer developed a wide-based gait following treatment on a clinical trial with cytotoxic chemotherapy and an anti-PD-L1 drug. 31414604 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Atezolizumab (Tecentriq<sup>®</sup>), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the randomized IMpower150 and IMpower130 studies in chemotherapy-naïve patients with nonsquamous metastatic NSCLC. 31728860 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE PD-L1 expression by immunohistochemistry (IHC) testing with Tumor Proportion Score (TPS) ≥50% and ≥1% is required to be eligible for first- and second-line Pembrolizumab treatment for metastatic non-small cell lung cancer (NSCLC) respectively. 31097091 2019